drugset / Trial / NCT00649220

Memantine and Antipsychotics Use

NCT00649220

Phase 4 Terminated 19 enrolled Merz Pharmaceuticals GmbH
NaSingle-groupOpen-labelTreatment

Summary

To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.

Timeline

Start
2008-07
Primary completion
2009-05
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown

Indications